NCT07116096

Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis

Recruiting now NA Last updated 13 January 2026

What this trial tests

NA trial testing Jamar Hand Dynamometer, Hand Dynamometer in Liver Cirrhosis in 120 participants. Currently enrolling.

Timeline

17 August 2025

Primary endpoint
15 August 2026

15 August 2026

Quick facts

Lead sponsor	Shanxi Provincial People's Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	120
Start date	17 August 2025
Primary completion	15 August 2026
Estimated completion	15 August 2026
Sites	2 locations across China

Drugs / interventions tested

• Jamar Hand Dynamometer, Hand Dynamometer

Conditions studied

• Liver Cirrhosis — all drugs for Liver Cirrhosis →
• Portal Hypertension — all drugs for Portal Hypertension →

Sponsor

Shanxi Provincial People's Hospital

Who can join

18 and older, any sex, with Liver Cirrhosis or Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Background Handgrip strength , a core indicator of muscle function, has been confirmed to be significantly associated with the clinical prognosis of patients with liver cirrhosis. However, no studies have explored its correlation with portal venous hemodynamics.
2. Objective The purpose of the study is to examine the effects of Handgrip strength on portal vein and left gastric vein pressure, blood flow velocity and direction in patients with liver cirrhosis, as well as its hemodynamic impact on gastroesophageal varices.
3. Method Study Design: Interventional study. Detection Timing: Hemodynamic indices were measured simultaneously after patients achieved their maximum handgrip strength. Participants were divided into three groups based on the assessment methods. Group 1 (Portal Pressure Measurement Group): Before the placement of TIPS, the pressures of the portal vein and left gastric vein were measured, both before and after the handgrip strength test. Group 2 (Doppler Ultrasound Measurement Group): Measurements of portal flow velocity and direction were taken before and after the handgrip strength test, based on Doppler ultrasound. Group 3 (Endoscopic Ultrasound Measurement Group): Measurements of blood flow volume and direction in esophagogastric varices were conducted before and after the handgrip strength test, based on endoscopic ultrasonography. The inclusion and exclusion criteria were described.
4. Elaboration of the Research Hypothesis 4.1. Core Hypothesis The handgrip strength level in patients with liver cirrhosis is correlated with portal venous system hemodynamic indices. Specifically, enhanced handgrip strength may affect portal hypertension and the hemodynamics of varicose veins by improving systemic muscle function or circulatory status.

4.2. Speculation on potential mechanisms Association between muscle function and circulation: As a representative of systemic muscle function, increased handgrip strength may reflect an increase in cardiac output or changes in splanchnic vascular resistance, thereby influencing portal venous hemodynamics.

Effects on varicose veins: Improved handgrip strength may reduce blood flow velocity or diameter of esophagogastric varices by decreasing splanchnic congestion or regulating local vascular tension, thus lowering the risk of variceal rupture and bleeding.

Role of compensatory mechanisms: Muscle wasting is common in decompensated cirrhosis. Patients with higher handgrip strength may have better compensatory capacity, and the degree of hemodynamic disorder in their portal venous system may be less severe.

Conclusion This study uses a multi-method grouping design to first explore the association between handgrip strength and portal venous hemodynamics in cirrhotic patients. The hypothesis is based on the potential regulatory role of muscle function in the circulatory system, which is expected to provide a new non-invasive indicator for clinical assessment of portal hypertension risk.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.